RESUMO
This study aimed to investigate the application effect of tirofiban on percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS) and its postoperative effect on C-X-C motif chemokine ligand 16 (CXCL16) level and myocardial perfusion. A total of 50 cases of patients diagnosed with acute coronary syndrome and treated in Sunshine Union Hospital (Weifang, China) were included in group A and 30 cases of healthy subjects underwent physical examination in our hospital during the same period were enrolled in group B. Tirofiban was used in group A patients during PCI. Clinical efficacy evaluation criteria were used to evaluate the efficacy after treatment. The level of CXCL16 in serum before and after treatment was detected by qRT-PCR. Receiver operating characteristic (ROC) curve was drawn to analyze the value of C-X-C Motif Chemokine Ligand in diagnosing ACS. Before treatment, CXCL16 level in group A was significantly higher than that in group B (p<0.001). After treatment, patients in TMPG grade 3 in group A were significantly increased (p<0.001). Tirofiban could improve myocardial perfusion in patients with ACS after PCI, reduce adverse events and CXCL16 levels. Serum CXCL16 is expected to be a potential diagnostic and therapeutic predictor of ACS.
